Add Company
Join Now

Opexa Therapeutics Revenue and Competitors

License our Company Data API

Houston, TX USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Opexa Therapeutics's estimated annual revenue is currently $4.3M per year.(i)
  • Opexa Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Opexa Therapeutics has 28 Employees.(i)
  • Opexa Therapeutics grew their employee count by 0% last year.

Opexa Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is Opexa Therapeutics?

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.

keywords:N/A

N/A

Total Funding

28

Number of Employees

$4.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.9M28-7%N/A
#2
$5.3M280%N/A
#3
$4.8M28-3%N/A
#4
$5M29N/AN/A
#5
$3.6M29-9%N/A